

Press release

Genomtec lines up technology trials with potential Asian partners during M&A efforts

Wrocław, February 12, 2026 – Genomtec S.A., a molecular diagnostics company based in Wrocław (WSE ticker: GMT), announced that it has undertaken key preparatory activities related to planned testing of Genomtec diagnostic devices in Asia. These activities are directly related to the ongoing M&A process and are a response to the demand expressed by potential partners in this region.

The current phase of preparatory work for the tests is organizational and analytical in nature and involves establishing a detailed scope and method of conducting local tests with stakeholders by Genomtec staff. The company is also focusing on analyzing logistical conditions, assessing the legal requirements for biosafety in the given region, and preparing and producing the appropriate number of reaction cards necessary for system validation.

Miron Tokarski, President of the Management Board and co-founder of Genomtec SA, comments:

"Undertaking preparatory steps for testing in Asia is an important step in the ongoing M&A process. The fact that potential partners with whom we are in talks have expressed a need to verify our technology in local conditions confirms the strong interest in Genomtec's solutions in the dynamically developing Asian market and the transition to the next stage of the M&A process. We are currently in the phase of intensive logistical and organizational preparations to efficiently conduct the tests."

The company's flagship project is the Genomtec ID® mobile diagnostic system, which consists of an analyzer and a reaction card with integrated genetic tests. The Genomtec ID® platform is based on the proprietary SNAAT® solution and stands out from the competition for its mobility, speed, and ability to simultaneously diagnose multiple pathogens at the point of care. The OncoSNAAT® project, in turn, is a technology for detecting genetic changes occurring in cancer, which is crucial in personalized medicine, for example, when selecting targeted oncology treatments.

About Genomtec:

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for quick and precise molecular analysis outside the laboratory environment without the need for qualified laboratory personnel. The solution utilizes microfluidic technology and proprietary, patented isothermal technology. SNAAT® Genomtec's technology is protected by 20 patents in Europe, the US, and Japan, among others, and the company has over 30 patent applications pending.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections

The company is headquartered in Wrocław. Genomtec also has a presence in the UK, where an office and part of its international research and engineering team are located.

More information is available on the company's website: www.genomtec.com



Media contact:

Michał Wierzchowski

Tel.: +48 531 613 067

michal.wierzchowski@ccgroup.pl

Contact for investors:

Agata Dzieciołowska

Tel.: +48 606 205 119

agata.dzieciolowska@ccgroup.pl